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Myelin encephalitogenic or basic protein (BP) 1 accounts for 30% of the protein 
in central nervous system (CNS) myelin (1), where BP is postulated to serve a 
structural role.  BP is unique to myelin, and a  similar,  if not identical,  protein 
designated P1 (2) is present in peripheral  nervous system (PNS) myelin (2-4). 
BP has a  monomeric  mol wt of 18,500  daltons  and  is comprised of 169 amino 
acids. The amino acid sequence has been determined for BP from human (5) and 
bovine (6) sources and the small BP of the rat (7). In addition to its extensively 
investigated  property  of  inducing  experimental  allergic  encephalomyelitis 
(EAE),  BP may also sensitize lymphocytes and stimulate antibody formation. 
Lymphocyte sensitization and antibody formation to BP may occur independent 
of each other and of EAE  (8-10).  The molecular portion of BP responsible for 
inducing EAE is different for the guinea pig (11), rabbit (12,  13), and Lewis rat 
(14), and there appear to be differences in the antigenic determinants recognized 
by guinea pig (15) and rabbit  (16) antibodies to BP. 
The conformation of BP is likely to be important in the stability of the myelin 
sheath and in influencing the immune response after injection.  The conforma- 
tion  of BP in the  CNS myelin membrane  and  in solution is unresolved  (17). 
While some studies have indicated that BP has only random-coil structure  (18- 
23) other investigations have provided findings suggestive of a prolate ellipsoid 
conformation  (24,  25).  In  a  previous  study  of the  antigenic  determinants  of 
bovine BP (16),  we reported that peptide 43-88 had limited participation  as an 
antigenic  determinant  recognized by complement  (C)-fixing antibodies in two 
rabbit  antisera  to  BP.  This  finding  prompted  speculation  that  peptide  43-88 
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might have an internal position in the BP molecule. The present study provides 
data strongly supportive of this possibility as well as suggesting that there are 
differences  in the region  of the  BP molecule  involving residues 43-88 and the 
comparable region of P1 in PNS myelin. 
Materials and Methods 
Materials.  Carboxymethyl (CM)-cellulose (CM52) was obtained from Reeve Angel, Clifton, N. 
J.,  carrier-free  125I from  Amersham/Searle  Corp.,  Arlington  Heights,  Ill.,  methylated  bovine 
serum albumin (MBSA) from Sigma Chemical Co., St.  Louis, Mo.,  a-chymotrypsin, pepsin, and 
trypsin  (treated  with  L-[tosylamido  2-phenyl]  ethyl  chloromethyl  ketone)  from  Worthington 
Biochemical Corp., Freehold, N. J., lactoperoxidase from Calbiochem, La Jolla, Calif., citraconic 
anhydride from Aldrich Chemical Co., Inc., Milwaukee, Wis., Bio-Gel P-2 from Bio-Rad Laborato- 
ries,  Richmond, Calif.,  Sephadex and AH Sepharose 4B from Pharmacia Fine Chemicals,  Inc., 
Piscataway,  N. J., guinea pig brain tissue from Pel-Freez Bio-Animals, Inc.,  Rogers, Ark.,  and 
plastic tubes (no. 2053) from Falcon Plastics, Div. of BioQuest, Oxnard,  Calif. Guinea pigs were 
obtained from Camm Research  Institute,  Inc.,  Wayne,  N.  J.  Bovine brain tissue was obtained 
from a  local slaughterhouse. 
Purification of BP.  Bovine BP and guinea pig BP  were purified by  extraction and cation- 
exchange chromatography (16).  The last major peak (16,  26), designated as component 1, 2 to elute 
from the CM-cellulose was used as the starting material for fragmentation. Components 1-4 from 
bovine BP were mixed and used for preparation of the BP solid-phase immunoadsorbent. Electro- 
phoresis of the individual BP components on polyacrylamide gels in acetic acid-urea (27) and at pH 
4.3  (28)  showed essentially one band. Combining the major components of bovine BP for use in 
solid-phase immunoadsorbence seemed justified since previous studies (26) have shown that these 
components probably do not differ in their amino acid sequence but differ because of modification 
by phosphorylation and/or deamidation reasonably restricted to specific sites in the polypeptide 
chain. 
Fragmentation of BP (Component 1).  Peptides  1-88, ~ 1-115,  20-166,  and 43-88 were prepared 
and isolated from BP component 1 (1-169)  as previously described (I6).  Peptides 43-88 and 1-88 
were obtained from limited peptic digests of BP, peptide 1-115 was derived from BP reacted with 
BNPS-skatole, and peptide 20-166 was generated from BP by cyanogen bromide fragmentation. 
Peptide 43-88  served as the starting material for the preparation for smaller peptides. Bovine 
peptide 43-88 was subjected to limited chymotrypsin digestion (protein to enzyme ratio, 1,000:1) to 
produce  peptides  43-67  (C2) and 68-88  (C1)  which were  separated on CM-cellulose and further 
purified on Sephadex GS0 (14).  Peptide 79-88 was prepared by tryptic digestion of the guinea pig 
peptide 43-88 pretreated with citraconic anhydride followed by regeneration in dilute acid.  The 
peptide was isolated on CM-cellulose and further purified on Sephadex G25 (14).  The guinea pig 
peptide 43-88 was used instead of the corresponding bovine peptide since it is not possible to obtain 
peptide 79-88 from the bovine peptide 43-88 because of a resistant Arg-Pro peptide bond at position 
78-79. The guinea pig peptide 79-88 differs from the corresponding bovine peptide by a single serine 
for proline substitution at position 79  (29).  Peptide 64-73 was prepared by treating guinea pig 
peptide 43-88 with trypsin at an enzyme:substrate ratio of 1:50 at pH 8, 37°C for 4 h. The peptide 
was eluted from CM-cellulose at pH 4 with a NaC1 gradient and was further purified on Sephadex 
G25 (14).  Peptide 64-73  has the same amino acid sequence in bovine and guinea pig BP (29). 
Characterization  of BP Fragments.  The  BP  fragments  were  characterized  by  amino  acid 
analysis and by analysis of tryptic peptides isolated from two-dimensional paper chromatography- 
high voltage electrophoresis peptide maps as described previously (16). 
Preparation ofAntisera.  3 mg of bovine BP peptide 43-88 were dissolved in 1.5 ml of distilled 
H20. After 3.2 mg of rabbit serum albumin (RSA) and 3.8 mg of 1-ethyl-3-(dimethylaminopropyl)- 
2 Component  1  designates  the  last  of the  six  components  to  elute  from  the  column.  This 
numbering system is that proposed by Deibler and Martenson (39) rather than that used by the 
present authors in a  previous publication (16). 
3 The numbering of residues of BP is based on the revised sequence  data of 169 amino acid 
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carbodiimide HCI were added, the solution  was stirred  at 25°C for  20 h and dialyzed  at  4°C for  4 
days against distilled  H~O. For  the primary immunization the peptide-RSA mixture was diluted 
with 0.01  M  phosphate-buffered 0.15  M  NaCI, pH 7.2,  and emulsified with complete Freund's 
adjuvant. Two 2-kg female New Zealand white rabbits (R95 and R96) were injected  with an 
inoculum  of  2  ml containing 200/~g  of  peptide  43-88.  Secondary  immunization  was  performed  4  wk 
later  with an identical  amount of  peptide in incomplete Freund's adjuvant. Boosting  immuniza- 
tions  of  the peptide-RSA immunogen containing 250 ~tg  of  peptide in 0.15  M  NaCI were injected 
intravenously at  monthly  intervals.  Blood  was  obtained after  the  second and  later  immunizations. 
For the detailed  immunochernical studies  described below, blood on R95 was obtained after  the 
second  intravenous boost  and  on R96 after  the fourth  intravenous boost.  Goat  anti-rabbit  IgG  was 
prepared as previously  described (4). 
Absorption of Anti-Peptide 43-88 with BP.  In order to remove antibodies to intact BP, a  BP- 
immunoadsorbent was prepared. 1 g ofAH Sepharose 4B was washed with 300 ml 0.5 M NaC1 and 
100 ml distilled HsO after which it was suspended in 10 ml distilled H20.15 mg each of bovine BP 
microheterogeneous  components 1-4 (total of 60 rag) were added, and the pH adjusted to 4.5 with 
0.1 N HC1. With the pH maintained at 4.5, 5 ml of distilled H20 containing 60 mg of 1-ethyl-3 (3- 
dimethylaminopropyl)-carbodiimide  HC1 was added. This mixture was gently agitated at 25°C for 
18 h, washed Successively with 200 ml distilled H20,  100 ml 0.5% acetic acid, and 200 ml borate- 
saline buffer (30, 31), and stored in the borate-saline buffer. 
The BP-AH Sepharose was placed in a 1.5 ×  5 cm column at 25°C and washed thoroughly with 
the borate-saline buffer. 2  ml of antiserum was passed through the column with the effluent 
monitored at 280 nm. After emergence of the unretarded serum material, the attached substances 
were eluted with 0.1  M glycine-HC1, pH 2.8,  in 0.1  M NaC1.  Both the flow-through and eluate 
fractions were dialyzed against phosphate-buffered  saline and concentrated by vacuum dialysis to 
2 ml. The BP-immunoadsorbent was regenerated by washing with the borate-saline buffer. 
Radioiodination of BP and Peptide  43-88.  BP  and peptide 43-88 were radioiodinated with 
carrier-free 125I by the lactoperoxidase method (32, 33). To a  12  × 75 mm polypropylene tube were 
added in sequence 40 ~10.3 M acetate buffer, pH 5.5,  10/~g of BP or BP peptide 43-88 in 5 ~l of the 
acetate buffer, 2.5 ~tg of lactoperoxidase in 10 ~tl of the acetate buffer, 10/~1 of 0.5 M NaH~PO,, and 
10/xl of 125I. 25/~l of  0.4 M H202 were added in five aliquots of  5/~1 each at 60-s intervals. 6 min after 
the initial addition of H202,  10 ~1 of 0.022 M KI was added. Radiolabeled antigen was separated 
from free iodine on a 0.7  x  13 cm Bio-Gel P-2 column equilibrated with 0.01 M HC1 containing 1 g 
of bovine serum albumin/100 ml (33). A single tube (0.25 ml) in the initial peak (approximately 
25% of the gel bed volume) containing the maximum number of counts per minute was used. The 
specific activity was calculated to be 20  ~Ci//~g for BP and 40  /~Ci//~g for peptide 43-88.  This 
indicated that 900 pg of 12sBP or 300 pg of ~2SI-BP-peptide 43-88 was added to each assay tube in 
the double-antibody radioimmunoassay (DA-RIA). 5% TCA precipitated 95-98%  of the counts per 
minute added with z~I-BP. At a concentration of 5% TCA, 70-80% of the counts per minute asso- 
ciated with radioiodinated peptide 43-88 were precipitable. This low percentage of precipitability 
may be due in part to the size of the polypeptide. Since only 90% of the ~I-peptide 43-88 could 
be precipitated with  low dilutions of certain anti-BP  peptide 43-88 antisera,  radioiodination- 
induced changes of peptide 43-88  must also be considered. Radiolabeled antigens were used no 
longer than 2 wk after radioiodination. 
Radioimmunoassays.  The DA-RIA was performed in a  total vol of 0.95  ml in 12  ×  75 mm 
polypropylene plastic tubes.  The assay mixture consisted of 0.2 M  Tris-acetate buffer, pH 7.2, 
containing 0.2 g MBSA (TA-MBSA)/100 ml, 0.2 ml of  rabbit antiserum appropriately diluted in the 
Tris-acetate buffer containing a 1:200 dilution of normal rabbit serum, known amounts of  BP or BP 
fragment in 50 ~1 of TA-MBSA, and 17,000-20,000  cpm of z~I-BP peptide 43-88 or ~I-BP in 50/~1 
of the Tris-acetate buffer. 
After the initial mixture had stood at 4°C for 20 h, 0.2 ml of goat anti-rabbit IgG was added and 
the mixture allowed to stand for 24 h at 4°C. The tubes were centrifuged, the pellet washed with 2 
ml of the Tris-acetate buffer, and the radioactivity of the pellet determined on an autogamma 
counter. In each DA-RIA all determinations of inhibition by peptides were done in triplicate. For 
those determinations of reactivity of antiserum or fractions thereof or of the optimal dilution of 
antiserum for studying inhibition by peptides in the DA-RIA, the assay was performed in a similar 
manner except that the unlabeled BP or BP fragments were omitted. 
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ml in the working buffer used for quantitative C fixation (4, 34) and diluted to the desired extent in 
TA-MBSA before the DA-RIA. For calculation of molar concentrations, peptides were assigned a 
molecular weight based on 100 daltons per amino acid residue. 
Other Methods.  The quantitative micro-complement fixation test (QMCT) (34) was performed 
as previously described (4).  Apparent association constants were calculated based on Scatchard 
analysis  (35,  36).  Indirect immunocytochemistry  was  performed  (4)  using cryostat  sections of 
guinea pig cerebellum and sciatic nerve. Tissue was processed and horseradish peroxidase (HRP)- 
Fab prepared as previously described (4) except that fixation was in methanol (98.3 parts)-H202 
(1.7 parts of 30% solution) at 25°C for 20 min. Guinea pig cerebellum and sciatic nerve were also 
obtained  from  animals  perfused  in  situ  with  4%  paraformaldehyde  in  Millonig's buffer  (38). 
Cryostat sections of perfused tissue were further fixed and processed as the cryostat sections of 
fresh frozen material. 
Results 
Fragmentation  ofBP Peptides.  Bovine BP peptides 43-88,  1-88,  1-115,  and 
20-166 were the same preparations as those previously described (16). Peptide 43- 
88 contained approximately 40% of peptide 37-88. Peptide 1-88 and 1-115 were of 
high purity, but peptide 20-166 was partially contaminated with intact BP. 
Limited chymotrypsin digestion cleaved peptide 43-88 at Tyr-Gly (residues 67- 
68) to produce peptides 43-67 and 68-88. Chymotrypsin also cleaved the contami- 
nating peptide 37-88 at Phe-Phe  (residues 42-43) to generate the small peptide 
37-42  which  was removed by subsequent purification  procedures  (14).  Amino 
acid and tryptic peptide map analysis showed these two major peptides, 43-67, 
68-88, to be of high purity (14). Approximately 40% of the preparation of peptide 
64-73 of guinea pig BP was contaminated with another peptide (Table I). Analysis 
of the two-dimensional peptide map prepared from this preparation showed that 
the contaminating peptide was peptide 52-56. Peptide 79-88 was of high purity as 
shown in Table I.  As noted above, this peptide differs from the corresponding 
bovine peptide in that there is a serine at position 79 rather than proline (29). 
Reactivity of  Anti-Peptide 43-88 with BP.  Serum obtained before immuniza- 
tion of both R95 and R96 had no antibody activity to bovine BP or peptide 43-88. 
After immunization,  antibody to peptide  43-88  was detected after the  second 
immunization  and  showed a  gradual  increase  in titer with repeated boosting 
(Figs.  1 and 2). The amount of radioiodinated peptide 43-88 precipitated never 
exceeded 90% even with antiserum dilutions as low as 1:100. 
In contrast to their reactivities with peptide 43-88, antisera from both R95 and 
R96 throughout the course of immunization did not contain appreciable amounts 
of antibody to intact BP (Figs. 1 and 2). R95 had slightly more antibody activity 
to BP than did R96. When these antisera were absorbed with the BP-immunoad- 
sorbent, antibody activity to peptide 43-88 was unchanged (Table II). The small 
amount of anti-BP activity was removed and recovered in the eluate. 
Studies  on  the  Antigenic  Site  of Peptide  43-88.  In  order  to  identify  the 
region of peptide reactive with these antisera and by inference "buried" in the 
BP  molecule,  inhibition  of the  DA-RIA  reaction  between  antisera  and  12~I- 
peptide 43-88 by various BP peptides was investigated. It was clearly shown that 
peptide 68-88 contained all of the reactant site(s) for R96 with none present in 
peptide 43-67 or peptide 64-73 (Fig. 3). On further fragmentation of peptide 43-88 
it could be shown that  all of the activity to peptide 68-88 in R96 was actually 
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TABLE  I 
Amino Acid Composition of Peptides Derived from BP Region 43-88 
Amino acid  43-67  68-88  64-73  79-88 
Lysine  1.9 (2)  1.0  (1)  1.6"(1) 
Histidine  2.5 (3)  2.1  (2)  1.0  (1)  0.8 (1) 
Arginine  3.0 (3)  0.8  (1)  0.6*(0) 
Aspartic acid  2.0 (2)  2.0  (2)  2.1  (2) 
Threonine  1.8 (2)  2.0  (2) 
Serine  1.8 (2)  0.9  (1)  1.8"(1)  0.8 (1) 
Glutamic acid  4.0  (4)  1.0  (1)  2.0 (2) 
Proline  0.9 (1)  2.9  (3)  1.0  (1)  1.0 (1) 
Glycine  4.8 (5)  1.8  (2)  2.2"(1) 
Valine  1.05(2}  0.7 (2) 
Leucine  1.0  (1)  0.8  (1) 
Tyrosine  0.9 (1)  0.8  (1) 
Phenylalanine  0.7 (1)  1.0  (1)  0.9 (1) 
1 mg of each peptide was hydrolyzed in 6 N  HC1 at 110°C for 48 h and the nanomoles per residue 
are based on the content of glutamic acid. 
* This peptide is contaminated with approximately 40% ofpeptide 52-56 (Arg-Gly-Ser-Gly-Lys). 
$ Low value of valine is due to a  Val-Val sequence. 
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FIG.  1.  Precipitation of radJoiodinated BP (dark bars) and peptide 43-88 (light bars) by a 
1:500  dilution  of R95  sera  obtained  at  varying  intervals  after  primary  immunization. 
Arrows ( ~ ) indicate times of immunization. Preimmune serum, diluted 1:100, precipitated 
neither antigen. 
Comparable to the findings using R96 serum,  R95 serum failed to react with 
peptides 43-67 and 64-73 (Fig. 4). However, the differences among peptides 43-88, 
68-88,  and  79-88  were  less  evident  with  these  three  peptides  having  nearly 
identical molar inhibitory activities (Fig.  4). 
Since both  antisera  reacted  well  with  peptide  43-88  and  to  a  very limited 
extent  with  intact  BP,  investigations  were  undertaken  to  determine  what 
fragments of BP containing peptide 43-88 would react with antibody to peptide 
43-88.  Intact  BP  and  peptide  1-115  had  little,  if any,  reactivity  with  either 
antiserum,  previously absorbed with BP,  at  100-fold higher  molar concentra- 
tions  (Figs.  5  and  6).  Peptide  20-166  demonstrated  some  reactivity  at  high 322  BURIED  DETERMINANT  OF  MYELIN  BASIC  PROTEIN 
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Fic.  2.  Precipitation of radioiodinated BP (dark bars) and peptide 43-88 (light bars) by a 
1:500  dilution  of R96  sera  obtained  at  varying  intervals  after  primary  immunization. 
Arrows ( ~ ) indicate times of immunization, Preimmune serum, diluted 1:100, precipitated 
neither antigen. 
TABLE  II 
Antibody Activity of Antisera Raised against Bovine BP Peptide 43-88 
Rabbit serum or serum 
fraction* 
% Precipitation of 125I-antigen 
Immunocytochemical reac- 
tion with: 
BP  Peptide 43-88  CNS myelin  PNS myelin 
R95 serum  13.0  43,7  +  + 
R95 serum BP-absorbed  4.6  45.1  +  0 
R95 serum BP-eluate  12.4  5.7  +  + 
R96 serum  4.3  44.7  +  + 
R96 serum BP-absorbed  2.8  40,8  +  0 
R96 serum BP-eluate  1.5  7.7  +  + 
* Diluted 1:500 for DA-RIA and 1:25 for immunocytochemistry. 
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FIG.  3.  Inhibition of  the reaction between R96, absorbed with bovine BP and diluted 1:750, 
and radioiodinated bovine peptide 43-88 by varying amounts of  peptides 43-88 (©), 43-67 (~,), 
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FIG.  4.  Inhibition of the reaction between R95, absorbed with bovine BP and diluted 1:450, 
and radioiodinated bovine peptide 43-88 by varying amounts ofpeptides 43-88 (©), 43-67 (~), 
68-88  (*),  64-73  (A), and 79-88  (O). 
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FIG.  5.  Inhibition  of  the reaction  between R96, absorbed with  bovine BP and  diluted  1:750, 
and radioiodinated bovine peptide 43-88 by BP (0) and peptides 43-88  (©), 1-88 (,), 1-115 
(A),  and 20-166 (A). 
concentrations. Peptide  1-88 had much greater reactivity and gave  a displace- 
ment curve parallel to peptide 43-88. 
Scatchard plots of the bound/free ratio of l~I-peptide 43-88 as a function of the 
binding of peptides  1-88,  43-88,  68-88,  and  79-88  were  used  to determine  the 
apparent association constant (Ka,,oc) and reflected the reactions of R95 (Table 
III)  and R96 (Fig. 7, Table III).  R95 serum had a lower Ka,,oc, 8.8  x  107 M -1, for 
peptide 43-88 than did R96 serum which had a Ka,,oc of 1  x  109 M -1. The Ka,,oc of 
R96 for peptides 68-88 and 79-88 was higher than for peptide 43-88. The associa- 
tion constants  shown by  R95  serum  for these  peptides  were  lower  but more 
nearly equal in magnitude (Table III). 
Results of studies using QMCT also suggest a difference in BP or peptide 43-88 
recognized by R95 serum but not by R96.  At a  1:100 dilution R95,  unabsorbed 324  BURIED  DETERMINANT  OF  MYELIN  BASIC  PROTEIN 
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FIG.  6.  Inhibition of  the reaction between R95, absorbed with bovine BP and diluted 1:450, 
and radioiodinated bovine peptide 43-88 by BP (0) and peptides 43-88  (©), 1-88 (I), 1-115 
(A), and 20-166 (A). 
TABLE  III 
Comparison of association constants 
Peptide  R95 serum  R96 serum 
43-88  1"  1 
68-88  1.2  4.1 
79-88  0.6  5.1 
1-88  0.4  0.02 
* Represents ratio of apparent K,,,oc for given BP peptide to apparent 
K,,,oc for BP peptide 43-88. Kassoc of  R95 serum for peptide 43-88 was 8.8 
×  107 M -1. K~,soc of R96 serum for peptide 43-88 was 1 x  109 M -1. 
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FIG.  7.  Binding of peptides 43-88,  67-88,  and 79-88 by R96 previously absorbed with BP. 
Bound/free ratio of radioiodinated peptide 43-88 plotted as a function of peptides 43-88 (©), 
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FIG.  8.  Indirect HRP-immunocytochemical  studies of R95 serum or fractions thereof re- 
acting with cryostat sections of  cerebellum (A-D) and peripheral nerve (E-H) removed from 
perfused guinea pigs.  Preimmune serum did not react with either CNS  (A) or PNS  (E) 
myelin. R95 serum reacted with beth CNS (B) and PNS (F) myelin. After exposure to a BP- 
immunoadsorbent, R95 serum continued to react weakly with CNS myelin (C) but showed 
no reactivity to PNS myelin (G). The antibodies  eluted from the BP-immunoadsorbent 
reacted with both CNS (D) and PNS (H) myelin. All antiserum or antiserum fractions were 
studied at a 1:25 dilution.  A-D, × 56; E-H, x  140. 
with BP, fixed low levels of C in the reaction with intact BP but not peptide 43- 
88. The extent of reaction, large concentrations of BP required,  and low dilution 
of antiserum used precluded hapten inhibition experiments with peptide 43-88 
and fragments of peptide 43-88.  At the same dilution  R96 reacted with neither 
BP nor peptide 43-88 in the QMCT. 
Irnmunocytochemical  Studies.  Because  the  two antisera  reacted with pep- 
tide 43-88 but not the intact BP molecule, studies were performed to determine 
the reactivity of these antisera with fixed CNS and PNS tissue.  Both R95 and 
R96 sera reacted with guinea pig CNS myelin at a  1:25 dilution before and after 
absorption  with BP  (Fig.  8,  Table II).  However,  differences  were encountered 
with the reaction to PNS myelin assessed at dilutions of 1:10 and 1:25.  R95 and 
R96 sera reacted with PNS myelin but,  after absorption with BP, this reaction 
was  no  longer  detected.  The  eluate  recovered from the  BP-immunoadsorbent 
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and its fraction eluted from the BP immunoadsorbent was less than that of R95. 
This paralleled the binding to BP in the DA-RIA (Table II) and may be a result 
of differences in antigenic sites recognized by these two antisera  (Table III). 
Discussion 
The present findings indicate that the conformation of BP peptide 43-88, used 
for immunization and immunochemical procedures, is different from the confor- 
mation of the same region as it exists in the BP molecule.  Furthermore,  the 
unreactivity of BP with antibodies to peptide 43-88  implies that some or all of 
this region has an internal  position in the BP molecule. 
The  evidence  may be summarized  as  follows: Antibodies  produced  in  two 
rabbits by immunization  with peptide 43-88  linked to RSA reacted well with 
radioiodinated  peptide 43-88  but had little or no reaction  with radioiodinated 
BP.  In both  instances  the  assumption  is made  that  iodination  did not  alter 
immunoreactivity.  Absorption of these antisera  with  a  BP-immunoadsorbent 
eliminated the small reactivity to BP in R95 but did not remove the antibody 
activity to peptide 43-88 in either. These findings indicate that in intact BP, both 
free in solution in radioiodinated form and attached to an immunoadsorbent, the 
portions 43-88 reacting with these antisera are inaccessible in the intact mole- 
cule. The lack of inhibition by BP of the reaction between the two antisera and 
peptide  43-88  provides  proof that  intact  BP  in  solution  and  not  previously 
exposed to  the  conditions  of radioiodination  or  linked  to  Sepharose  is  also 
incapable of furnishing  an accessible antigenic site for attachment of the anti- 
bodies raised to peptide 43-88. The failure of the BP-immunoadsorbent, prepared 
with a  mixture  of microheterogeneous BP components 1-4  (26,  39),  to remove 
antibodies  to  peptide  43-88  suggests  that  this  inaccessibility  is  likely  to  be 
present  in  each  of the  microheterogeneous  fractions  as  they are  attached  to 
Sepharose. 
Efforts to further localize the portion of 43-88 bearing the antigenic determi- 
nant  indicated  that  such  was  located  in  peptide  68-88.  Since  most  protein 
antigenic  determinants  delineated possess approximately six amino acid resi- 
dues  (40,  41),  this  peptide  might  still  have  more than  one  determinant.  No 
appreciable activity against peptide 64-73 existed, but peptide 79-88 was potent 
as an inhibitor, especially with R96 serum. This finding would indicate that the 
antigenic region of 43-88 reacting with R96 serum is in the region containing 
residues  79-88.  The  equal  reactivity of guinea pig peptide  79-88  with  bovine 
peptide 68-88  suggests that the proline residue at position 79,  which is substi- 
tuted  with  a  serine  in  guinea  pig  BP  (29),  is  probably  not  critical  for  the 
antigenic determinant in peptide 79-88 recognized by this rabbit antiserum. The 
antigenic region recognized by R95 also resided within region 68-88 but was not 
so restricted  to  peptide  79-88.  This  could indicate  that  a  different  or  second 
determinant exists in peptide 68-88 that does not lie within peptide 79-88.  The 
findings  with  R96 permit  one to  conclude that  the  antigenic  determinant  in 
region 79-88 is "buried" in the BP molecule. Whether some or all of the region of 
residues 43-78  are also buried cannot be determined  with these two antisera; 
however, the findings with R95 are consistent with some of 43-88 outside 79-88 
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The point in the fragmentation of BP at which the antigenic determinants are 
exposed was explored by using large BP peptides of 1-88, 1-115, and 20-166. It 
should also be recognized that the contamination of BP or of the preparations of 
peptides 1-88, 1-115, or 20-166 by smaller fragments containing peptide 79-88 
could alter the apparent reactivities of  these three large peptides. Although this 
cannot be totally discounted, the gel filtration steps utilized and the results of 
amino acid analysis make such a  contamination unlikely. The much greater 
reactivity of peptide 1-88 as compared to peptide 1-115 suggests that at least a 
portion of the region of BP encompassing residues 89-115 participates in the 
conformational alignment of BP which restricts access to region 79-88. A sharp 
bend in the BP molecule around the tri-proline residues of 98-100 has previously 
been postulated (42). High resolution nuclear magnetic resonance spectroscopy 
of bovine BP also indicates molecular folding in the region of residues 84-115 
(43). Although the reactivity of peptide 20-166 was evident only at high concen- 
trations,  its  greater reactivity than either intact  BP or peptide  1-115 could 
indicate that the removal of residues 1-19 may effect a  slight conformational 
alteration that increases exposure of region 68-88. 
The immunocytochemical studies provide proof that peptide 43-88 does not 
have a shielded position in CNS myelin fixed by the described procedures. Both 
antisera, even after absorption with BP, continued to react with CNS myelin. In 
contrast, reactivity with PNS myelin was abolished by absorption with BP but 
recovered in the eluate from the BP-immunoadsorbent. This suggests that BP 
and its cross-reactant, presumably P1 (2), in PNS myelin have compositional or 
conformational differences involving peptide 43-88 in BP and the comparable 
region of P1. Such differences might account for selective involvement of CNS 
myelin by immune processes directed at BP. A  more detailed immunological 
comparison of BP and P1 will require purified P1 protein. 
The inaccessibility of molecular regions and potential antigenic sites has been 
demonstrated for fragment A of diphtheria toxin (44), fragment A  in cholera 
enterotoxin  (45),  a  portion of tetanus toxin  (46), and the  pepsin moiety in 
pepsinogen (47). Other proteins such as hemocyanin (48), human serum albu- 
min (49), bovine serum albumin (50), RSA (51), human immunoglobulin (52), 
and rabbit immunoglobulin (53) contain determinants that are sequestered in 
the molecule. Some of the differences between the immunochemical reactivities 
of a protein fragment and its parent molecule may be due to the immunochemi- 
cal method used and a  requirement for multivalent antigens.  For example, 
antibodies to peptide 99-126 of staphylococcal nuclease do not precipitate peptide 
99-149 or intact nuclease (54). However, these antibodies bind to radiolabeled 
peptide 99-149 (54, 55), and this binding can be inhibited by intact nuclease (55). 
In the present study the reduced or absent reactivity between antibodies to BP 
peptide 43-88 and intact BP was demonstrated by methods which are affected by 
a single binding site. 
These immunochemical findings may reflect a special role for peptide 43-88 or 
adjacent region of BP in the host immune response to BP, the metabolism of BP, 
and the alignment of BP in the myelin membrane. In the molecular region of 
residues 64-121 there occur the major encephalitogenic sites for the rabbit (13), 
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and glycosylation (56) at threonine-97, and a methylated arginine at residue 106 
(57).  The  relationship  of T-lymphocyte responsitivity  to peptide  43-88  to  the 
induction of EAE in rats has also been documented (33).  Results of the present 
investigation have more general immunological implications regarding BP and 
other antigens in demonstrating that apparently distinct immunochemical reac- 
tions with tissue components may arise, not on a basis of different identities, but 
from  the  exposure  of shielded  antigenic  regions.  To  the  contrary,  immune 
responses  to  a  '~buried"  determinant  may go undetected  and  cross-reactions 
missed if only the parent protein is used as antigen in immunological studies. 
Summary 
The conformation of myelin encephalitogenic or basic protein (BP) was inves- 
tigated with a  double-antibody radioimmunoassay by studying the reaction of 
BP or its fragments with antibodies produced in two rabbits against peptide 43- 
88 linked to rabbit serum albumin. Both antisera reacted well with peptide 43-88 
but showed little or no reaction with BP. Absorption of these antisera with a BP- 
immunoadsorbent did not remove the antibody activity against peptide 43-88. 
Within the region of peptide 43-88  it was shown that peptides 68-88 and 79-88 
gave an equivalent or better reaction than peptide 43-88, whereas peptides 43-67 
and 64-73 had very little reactivity. In the BP fragments containing region 43-88, 
peptide 1-88 showed the best reactivity, peptide 20-166 showed minimal reactiv- 
ity, while peptide 1-115 showed none. 
These data document the internal position of at least a portion of peptide 43- 
88 and all of residues 79-88 in the BP molecule. The much greater reactivity of 
peptide 1-88 as compared to peptide 1-115 suggests that the region or a portion of 
the region of BP containing residues 89-115 participates  in the conformational 
alignment  of BP restricting access to peptide 79-88.  After absorption with BP, 
neither  of the antisera  prepared  to peptide 43-88 reacted with PNS myelin in 
fixed tissue sections but continued to react with CNS myelin in similarly treated 
sections.  The  present  findings  demonstrate  the  need  to  consider  the  role  of 
shielded antigenic determinants in the investigation of antigens or of immune 
responses. 
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